Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardio Diagnostics Holdings (CDIO) Cash & Equivalents (2021 - 2025)

Cardio Diagnostics Holdings' Cash & Equivalents history spans 5 years, with the latest figure at $8.0 million for Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 508.07% year-over-year to $8.0 million; the TTM value through Jun 2025 reached $8.0 million, up 508.07%, while the annual FY2024 figure was $7.8 million, 509.84% up from the prior year.
  • Cash & Equivalents for Q2 2025 was $8.0 million at Cardio Diagnostics Holdings, up from $7.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $9.7 million in Q2 2022 and bottomed at $9681.0 in Q3 2021.
  • The 5-year median for Cash & Equivalents is $2.8 million (2023), against an average of $3.8 million.
  • The largest annual shift saw Cash & Equivalents soared 92493.82% in 2022 before it plummeted 76.7% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $512767.0 in 2021, then surged by 703.0% to $4.1 million in 2022, then crashed by 68.83% to $1.3 million in 2023, then surged by 509.84% to $7.8 million in 2024, then grew by 1.78% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for CDIO's Cash & Equivalents are $8.0 million (Q2 2025), $7.8 million (Q4 2024), and $2.0 million (Q3 2024).